clinical trial · NCT04931342
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Ovarian CancerIpatasertibCobimetinibTrastuzumab EmtansineAtezolizumabBevacizumabPaclitaxelGiredestrantAbemaciclib
brief summary
This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.
started
Oct 7, 2021
primary completion
Feb 28, 2028
completion
May 30, 2028
last updated
Jun 8, 2026
official title
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol